Hepatitis
Hepatitis 01/03/2012
Hepatitis E uncommon among HIV+ people, but may cause unexplained liver enzyme elevations
Coinfection with hepatitis E virus is not commonly seen in people with HIV, but it is a possibility to consider if a person has elevated liver enzymes not attributable to another apparent cause.
Hepatitis 01/03/2012
In 2015, Gilead’s GS-7977 plus ribavirin will earn Decision Resources’ proprietary clinical gold standard status for the treatment of non-responder patients with hepatitis C virus
GS-7977 plus ribavirin will displace the current proprietary clinical gold standard, telaprevir in combination with peg-IFNα/ribavirin, according to findings from Decision Resources.
Hepatitis 25/02/2012
Vertex announces 12-week on-treatment data and SVR4 from Phase 2 study of interferon-free (all-oral) treatment regimen of INCIVEK®, VX-222 and ribavirin in people with genotype 1 hepatitis C
Company plans to start Phase 2b study in Q3 2012 to evaluate this interferon-free combination regimen in a total treatment duration as short as 12 weeks; Vertex also announces the advancement of its broad portfolio of direct acting antivirals, including its two structurally-distinct nucleotide polymerase inhibitors.
Hepatitis 25/02/2012
Interferon-based therapy reduces liver fibrosis progression in HIV/HCV coinfected patients
Interferon-based treatment for chronic hepatitis C helps slow liver disease progression among HIV/HCV coinfected patients as it does for people with hepatitis C alone.
Hepatitis 22/02/2012
Enanta enters into strategic collaboration to advance NS5A inhibitor candidate for HCV
Enanta has received IND approval for EDP-239 from the FDA.
Hepatitis 21/02/2012
Hepatitis C protease inhibitor therapy cost effective in some circumstances
A study supports the important role of protease inhibitors in treating chronic HCV for patients with advanced fibrosis as part of a first-line regimen.
Hepatitis 21/02/2012
Hepatitis C surpasses HIV as a cause of death in the US
There is a downward trend in HIV-related mortality, but incidence of deaths due to hepatitis C is increasing.
Hepatitis 17/02/2012
HCAB position statement: Hepatitis C drug development and drug-drug interaction studies
HCAB asks FDA, EMA and pharmaceutical companies to work together to minimize potential harm to hepatitis C monoinfected and HIV/HCV coinfected patients from uncharacterized drug-drug interactions.
Hepatitis 17/02/2012
European Medicines Agency informs doctors and patients about drug interaction between Victrelis and ritonavir-boosted HIV protease inhibitors
Some combinations no longer recommended; careful monitoring required.
Hepatitis 17/02/2012
Big step toward vaccine for hepatitis C
A researcher has made the discovery of a vaccine that will potentially help combat hepatitis C.
Hepatitis 17/02/2012
Gilead announces data for genotype 1 null responder hepatitis C patients enrolled in ELECTRON study
Viral relapse seen post treatment with GS-7977 plus ribavirin; Awaiting data for treatment-naïve genotype 1 patients.
Hepatitis 15/02/2012
Gilead, Vertex and the mystery of missing hep C patients
Why is everyone obsessed with hepatitis C?
Hepatitis 15/02/2012
Drugmakers vie for piece of future hepatitis C combo pill
A developing medical theory that hepatitis C can be overcome with the same type of drug cocktails that tamed HIV may drive acquisition strategies as companies try to anticipate which products work best with other medicines.
Hepatitis 15/02/2012
BioCryst announces promising results from preclinical studies of BCX5191 for hepatitis C
BCX5191: Planning to file for first—in-human studies during the fourth quarter 2012.
Hepatitis 13/02/2012
Phase 3 data on HEPLISAV(TM) in adults aged 18-55 published in VACCINE
Data from this study will be used to support the HEPLISAV Biologics License Application submission for an indication in adults 18-70 years of age.
Hepatitis 08/02/2012
Professional tattooing in sterile environment not associated with risk of hepatitis C
However, there is evidence that tattooing in non-sterile environments, such as prisons, is associated with the infection.
Hepatitis 08/02/2012
Merck warns of Victrelis and HIV protease inhibitor interactions
The hepatitis C protease inhibitor Victrelis has some significant drug-drug interactions with common Norvir–boosted protease inhibitor combinations.
Hepatitis 07/02/2012
BioLineRx in-licenses second oral hepatitis C treatment
BioLineRx has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030.
Hepatitis 03/02/2012
Idenix announces removal of the partial clinical hold on HCV nucleotide inhibitor, IDX184
The Company's 12-week phase IIb study evaluating IDX184 in combination with pegylated interferon and ribavirin may continue.
Hepatitis 01/02/2012
Stem cells could drive hepatitis research forward
By creating liver-like cells, scientists can study why people respond differently to the disease.
More...
